Eagle Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eagle Pharmaceuticals, Inc.
Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled
In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.
Industry Polarized In Best Manufacturing Approach For Cell And Gene Therapy
Ongoing debate emanates from industry players around the most efficient design of the manufacturing process for cell and gene therapies. The arguments surrounding outsourcing, centralizing, and standardizing processes will no doubt continue through into the near future.
Orphan Drug Exclusivity: In Narrow Application Of Catalyst Ruling, FDA Retains Its Existing Regs
US FDA will continue to tie orphan exclusivity to uses or indications for which the drug was approved. Attorneys say this buys agency time to sort out complex policy and legal questions and continue to seek legislative fix. Additional litigation is also possible, as happened in Depomed case.
Teva Lowers Forecast As Q3 Revenues Decline Amid Growing Generic Competition
The Israeli firm’s third-quarter revenues and profits decreased as its product sales dipped due to alternative options and generic competition leading it to lower its full-year guidance, but its opioid crisis financial settlement remains on track.
- Generic Drugs
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Arsia Therapeutics
- Eagle Biologics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.